Inventia Life Science is advancing 3D bioprinting technology to revolutionise biomedical research and regenerative medicine.
The company's strong foundation of fundamental research has led to the development of a proprietary platform encompassing bioprinting technology, an expanding library of printable bioink materials and custom protocols for specific applications.
The RASTRUM platform is now available to enable efficient and powerful bioprinting of 3D cell-based assays for biomedical research.
Location: Australia, New South Wales, Sydney
Employees: 11-50
Total raised: $35M
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | Main Seque... | mseq.vc/ |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.12.2021 | Series B | $35M | Blackbird ... |
Mentions in press and media 14
| Date | Title | Description |
| 08.06.2023 | From infinite recycling to bat-like vision for blind people: Cicada Innovations announces the Tech23 startups | SYDNEY, June 8, 2023 /PRNewswire/ -- Australia's flagship deep tech incubator Cicada Innovations has announced its first cohort of deep tech founders chosen to showcase their world-changing innovations at Australia's longest-running annual ... |
| 16.02.2023 | Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery | Collaboration to develop 3D in vitro models of the brain for the discovery of therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™ SYDNEY, Feb. 16, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science, a... |
| 17.01.2023 | Cicada Innovations acquires Tech23, celebrates $5.7b in combined capital raised | SYDNEY, Jan. 17, 2023 /PRNewswire/ -- Australia's national deep tech incubator Cicada Innovations has acquired custodianship of Australia's longest-running annual deep technology conference Tech23 as the capital raised by their deep tech co... |
| 14.07.2022 | Nuclera raises another $15.5M towards launch of gene protein 3D bioprinting technology | Biotechnology start-up Nuclera has attracted a further $15.5 million in Series B funding, taking its total raised in the round up to $58 million. Much like the initial $42.5 million it raised earlier this year, Nuclera plans to use this add... |
| 09.06.2022 | BIOLIFE4D seeking to finance heart 3D bioprinting plans via $17.5M IPO in the US | Biotechnology specialist BIOLIFE4D has filed for an Initial Public Offering (IPO) with the US Securities and Exchange Commission (SEC). Though BIOLIFE4D has yet to price its IPO, it has revealed that it aims to raise $17.5 million via the m... |
| 31.05.2022 | Regemat 3D raises over €500k in effort to advance its 3D bioprinting technology | Spanish 3D bioprinting specialist Regemat 3D has raised more than €500,000 in equity crowdfunding. Announced late last year, the funding round has seen Regemat 3D gain the backing of over 500 investors, for its plans to ramp up the marketin... |
| 02.03.2022 | OPT Industries secures $15M to advance 3D printing metamaterials design | Novel materials developer and MIT spin-out OPT Industries has raised $15 million in Series A funding to scale up the development of its novel 3D printing metamaterials and products. The capital injection will also be funneled into scaling u... |
| 07.02.2022 | Live human tendon 3D printed by scientists with new ‘cryo-bioprinting’ | 3D Printing Industry is currently seeking feedback on resin 3D printing. Send your insights now and take the Spotlight on Resin 3D Printing Survey. Researchers at Harvard Medical School and Sichuan University have developed a novel means of... |
| 02.02.2022 | Nuclera raises $42.5M towards launch of new protein 3D printer that “makes drug discovery accessible” | Insiders and analysts have made their predictions on the 3D printing trends to watch out for. Find out more in our series focused on the future of 3D printing. Biotechnology start-up Nuclera has raised $42.5 million towards the launch of a ... |
| 31.01.2022 | Matricelf licenses patent for 3D bioprinting tissues and organs from TAU | Israeli regenerative medicine firm Matricelf has signed an exclusive global licensing agreement with Tel Aviv University (TAU) technology transfer firm Ramot for a patent-pending 3D bioprinting technology. According to Globes, the technique... |
Show more